Compugen to Enter Research Collaboration with Mount Sinai on Novel Myeloid Immuno-Oncology Targets
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with Mount Sinai, under the direction of Miriam Merad, MD, PhD, Director of the …
InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay
InDevR, a Boulder-based progressive analytical technology and life science instrumentation company today announced that it has entered into an exclusive, world-wide license agreement for monoclonal antibodies developed by scientists at the Icahn School of Medicine at Mount Sinai. The license agreement with Mount …
Mount Sinai Health System Partners With Contessa Health to Expand Hospital-Level Care at Home Program
The Mount Sinai Health System announced today that it has partnered with Contessa Health, an innovative health care company that manages acute-care services at home through prospective bundled payment arrangements, to extend Mount Sinai’s existing hospital-level care at home program, known as …
Technology from a Mount Sinai Startup (Cardea Sciences) That Will Improve Outcomes for Cardiac Patients Wins the NYC Life Science Innovation Showcase
July 18, 2017 – Technology for identifying at-risk atrial fibrillation (AFib) patients was chosen as the winner of the inaugural Alexandria LaunchLabs Scholarship Award, which recognizes excellence in health care technology, entrepreneurship and business competencies. The technology, developed by a Mount Sinai …
Breathing in a New Gene Therapy to Treat Pulmonary Hypertension
June 12, 2017- Mount Sinai has partnered with Theragene Pharmaceuticals, Inc. to advance a novel airway-delivered gene therapy for treating pulmonary hypertension (PH), a form of high blood pressure in blood vessels in the lungs that is linked to heart failure. If …
Mount Sinai, Pfizer Renew Research Collaboration, Building on Strong Foundation
June 28, 2017 – The Icahn School of Medicine at Mount Sinai and Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) recently announced the renewal of an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid …
Treating Depression with Software: Technology from Mount Sinai Steps into the Digital Healthcare Universe
June 7, 2017 – A treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major depressive disorder (MDD) symptoms compared to a control group, according to initial …
Engineering New Anti-Cancer Drugs from Old Medicines
May 25, 2017 – An interdisciplinary collaboration including 45 researchers has discovered a new class of drug candidates that activates the tumor suppressor protein PP2A. These new compounds have been shown to inhibit the growth of lung cancer tumors in mice, and have …
RGFP996; A SPECIFIC HDAC3 INHIBITOR FOR TREATING ACUTE SPINAL CORD INJURY
There are approximately 12,500 new cases of acute SCI (spinal cord injury) each year in the United States, with that number expected to rapidly increase with the rise in the aging population. The only current treatment for SCI, albeit controversial, is the use …